Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to -$2.8 billion.

  • Amicus Therapeutics' Retained Earnings changed 0.0% to -$2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of -$2.7 billion for FY2024, which is 209.03% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Retained Earnings is -$2.8 billion, which was down 0.0% from -$2.8 billion recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Retained Earnings peaked at -$2.1 billion during Q1 2021, and registered a low of -$2.8 billion during Q3 2024.
  • Moreover, its 5-year median value for Retained Earnings was -$2.6 billion (2023), whereas its average is -$2.6 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 1518.02% in 2021, then changed by 0.0% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Retained Earnings (Quarter) stood at -$2.3 billion in 2021, then dropped by 10.3% to -$2.5 billion in 2022, then fell by 5.99% to -$2.7 billion in 2023, then decreased by 2.09% to -$2.7 billion in 2024, then fell by 2.18% to -$2.8 billion in 2025.
  • Its Retained Earnings was -$2.8 billion in Q3 2025, compared to -$2.8 billion in Q2 2025 and -$2.8 billion in Q1 2025.